Clinical Trial Update: Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

View source ↗

Summary

This post-marketing surveillance update assesses the safety of Cabometyx in Korean patients with Renal Cell Carcinoma, Hepatocellular Carcinoma, and Differentia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Sponsor: Ipsen | Conditions: Renal Cell Carcinoma, Hepatocellular Carcinoma | Status: COMPLETED